Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – What’s Next?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares gapped down prior to trading on Wednesday. The stock had previously closed at $17.92, but opened at $17.26. Daiichi Sankyo shares last traded at $18.1650, with a volume of 3,337 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Monday, September 21st. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Hold rating. According to data from MarketBeat, Daiichi Sankyo presently has an average rating of “Hold”.

Daiichi Sankyo Trading Up 1.1%

The business has a fifty day moving average of $17.79 and a 200-day moving average of $17.16. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. The company has a market capitalization of $33.74 billion, a P/E ratio of 21.06, a PEG ratio of 1.85 and a beta of -0.11.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.